Cells (Jan 2023)

RHOA Therapeutic Targeting in Hematological Cancers

  • Juliana Carvalho Santos,
  • Núria Profitós-Pelejà,
  • Salvador Sánchez-Vinces,
  • Gaël Roué

DOI
https://doi.org/10.3390/cells12030433
Journal volume & issue
Vol. 12, no. 3
p. 433

Abstract

Read online

Primarily identified as an important regulator of cytoskeletal dynamics, the small GTPase Ras homolog gene family member A (RHOA) has been implicated in the transduction of signals regulating a broad range of cellular functions such as cell survival, migration, adhesion and proliferation. Deregulated activity of RHOA has been linked to the growth, progression and metastasis of various cancer types. Recent cancer genome-wide sequencing studies have unveiled both RHOA gain and loss-of-function mutations in primary leukemia/lymphoma, suggesting that this GTPase may exert tumor-promoting or tumor-suppressive functions depending on the cellular context. Based on these observations, RHOA signaling represents an attractive therapeutic target for the development of selective anticancer strategies. In this review, we will summarize the molecular mechanisms underlying RHOA GTPase functions in immune regulation and in the development of hematological neoplasms and will discuss the current strategies aimed at modulating RHOA functions in these diseases.

Keywords